Reiter’s Syndrome Treatment Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2017-2027 Segmented By Drug Type (Antibiotics, Corticosteroids, Nonsteroidal anti-inflammatory drugs (NSAIDs), Immunosuppressive Drugs, Others), By Dosage Form (Tablets, Injections, Others), By Route of Administration (Oral, Intravenous, Others), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), By End User (Hospitals & Clinics, Ambulatory Care Centers, Others), By Region

December 2022 | 116 pages | ID: R9C01A00E358EN
TechSci Research

Abstracts

Global Reiter’s syndrome treatment market is projected to register CAGR growth in the forecast years, 2023-2027 on the account of growth factors like increasing instances of reactive arthritis, along with the advancement of the treatment processes and methods. Moreover, advancing healthcare industry for the better availability of the patient care suffering from severe conditions like reactive arthritis, is also responsible for the growth of the global Reiter’s syndrome treatment market in the upcoming five years.

Reiter’s syndrome is also known as reactive arthritis, which is a form of inflammatory arthritis. It is the joint disease that causes painful inflammations. The disease is a reaction to a bacterial infection. These bacteria are often found in genitals like Chlamydia trachomatis or in bowel like Campylobacter, Salmonella, Shigella and Yersinia. Genital bacteria transmit through sex and usually does not show major symptoms. In certain cases, a pus-like or watery discharge from the genitals is observed. Whereas bowel bacteria usually cause diarrhea along with discharge and can be considered as minor symptoms of Reiter’s syndrome.

Increasing Instances of Reiter’s Syndrome Drives Market Growth

Rapidly increasing instances of reactive arthritis and surging demand for the effective treatment of the same in driving the growth of the global Reiter’s syndrome treatment market in the upcoming five years. Reactive arthritis is a rare form of arthritis when compared to other forms of arthritis. More than 350 million patients of arthritis are currently suffering as of 2021 in the entire world. According to CDC, In the United States, 24% of all adults, or 58.5 million people, have arthritis. 1 in every 4 adults has arthritis and reports severe joint pain.

Whereas twenty-seven per 100,000 population globally suffers from Reiter’s syndrome, that majorly affects the adult males between 20-40 years of age. Growing population, increasing instances of unprotected sexual intercourse, increase the chances of the population contracting the disease and thus aiding to the growth of the global Reiter’s syndrome treatment market in the next five years.

Market Segmentation

The global Reiter’s syndrome treatment market segmentation is based on drug type, dosage form, route of administration, distribution channel, end user, regional distribution, and competitive landscape. Drug type market segment is further fragmented into antibiotics, corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), immunosuppressive drugs, and others. Based on dosage form, the market is sub-segmented into tablets, injections, and others. Market segmentation on the basis of route of administration, is further bifurcated into oral, intravenous, and others. Distribution channel segment is differentiated further among retail pharmacies, hospital pharmacies, and online pharmacies. The end user segment analysis the market fragments among hospitals & clinics, ambulatory care centers, and others. The market analysis also studies the regional segmentation, divided among Asia-Pacific region, North American region, European region, South American region, and Middle East & African region.

Company Profile

F. Hoffmann-La Roche AG, Pfizer, Inc., Novartis AG, Cipla Inc., Dr. Reddy’s Laboratories Ltd., Abbott Laboratories, Inc., GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd, AstraZeneca, Plc., are enlisted in a partial list of major market players of the global Reiter’s syndrome treatment market.

Report Scope:

In this report, global Reiter’s syndrome treatment market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

• Reiter’s Syndrome Treatment Market, By Drug Type:
• Antibiotics
• Corticosteroids
• Nonsteroidal anti-inflammatory drugs (NSAIDs)
• Immunosuppressive Drugs
• Others
• Reiter’s Syndrome Treatment Market, By Dosage Form:
• Tablets
• Injections
• Others
• Reiter’s Syndrome Treatment Market, By Route of Administration:
• Oral
• Intravenous
• Others
• Reiter’s Syndrome Treatment Market, By Distribution Channel:
• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies
• Reiter’s Syndrome Treatment Market, By End User:
• Hospitals & Clinics
• Ambulatory Care Centers
• Others
• Reiter’s Syndrome Treatment Market, By Region:
• North America
• United States
• Mexico
• Canada
• Europe
• France
• Germany
• United Kingdom
• Italy
• Spain
• Asia-Pacific
• China
• India
• Japan
• South Korea
• Australia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• South America
• Brazil
• Argentina
• Colombia

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global Reiter’s syndrome treatment market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Contents

1. PRODUCT OVERVIEW

2. RESEARCH METHODOLOGY

3. IMPACT OF COVID-19 ON GLOBAL REITER’S SYNDROME TREATMENT MARKET

4. EXECUTIVE SUMMARY

5. VOICE OF CUSTOMER

5.1. Preference, By Drug Type
5.2. Factors Contributing to Higher Demand of Reiter’s Syndrome Treatment
5.3. Barriers to Adoption of Reiter’s Syndrome Treatment
5.4. Brand Awareness

6. CLINICAL TRIALS

6.1. Ongoing Clinical Trials
6.2. Completed Clinical Trials
6.3. Terminated Clinical Trials
6.4. Clinical Trial Analysis

7. PATENT ANALYSIS

7.1. Patent Granted (2016-2020)
7.2. Patent Applications Filed

8. GLOBAL REITER’S SYNDROME TREATMENT MARKET OUTLOOK

8.1. Market Size & Forecast
  8.1.1. By Value
8.2. Market Share & Forecast
  8.2.1. By Drug Type (Antibiotics, Corticosteroids, Nonsteroidal anti-inflammatory drugs (NSAIDs), Immunosuppressive Drugs, Others)
  8.2.2. By Dosage Form (Tablets, Injections, Others)
  8.2.3. By Route of Administration (Oral, Intravenous, Others)
  8.2.4. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)
  8.2.5. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  8.2.6. By Company (2021)
  8.2.7. By Region
8.3. Product Market Map

9. NORTH AMERICA REITER’S SYNDROME TREATMENT MARKET OUTLOOK

9.1. Market Size & Forecast
  9.1.1. By Value
9.2. Market Share & Forecast
  9.2.1. By Drug Type
  9.2.2. By Dosage Form
  9.2.3. By Route of Administration
  9.2.4. By Distribution Channel
  9.2.5. By End User
  9.2.6. By Country
9.3. North America: Country Analysis
  9.3.1. United States Reiter’s Syndrome Treatment Market Outlook
    9.3.1.1. Market Size & Forecast
      9.3.1.1.1. By Value
    9.3.1.2. Market Share & Forecast
      9.3.1.2.1. By Drug Type
      9.3.1.2.2. By Dosage Form
      9.3.1.2.3. By Route of Administration
      9.3.1.2.4. By Distribution Channel
      9.3.1.2.5. By End User
  9.3.2. Mexico Reiter’s Syndrome Treatment Market Outlook
    9.3.2.1. Market Size & Forecast
      9.3.2.1.1. By Value
    9.3.2.2. Market Share & Forecast
      9.3.2.2.1. By Drug Type
      9.3.2.2.2. By Dosage Form
      9.3.2.2.3. By Route of Administration
      9.3.2.2.4. By Distribution Channel
      9.3.2.2.5. By End User
  9.3.3. Canada Reiter’s Syndrome Treatment Market Outlook
    9.3.3.1. Market Size & Forecast
      9.3.3.1.1. By Value
    9.3.3.2. Market Share & Forecast
      9.3.3.2.1. By Drug Type
      9.3.3.2.2. By Dosage Form
      9.3.3.2.3. By Route of Administration
      9.3.3.2.4. By Distribution Channel
      9.3.3.2.5. By End User

10. EUROPE REITER’S SYNDROME TREATMENT MARKET OUTLOOK

10.1. Market Size & Forecast
  10.1.1. By Value
10.2. Market Share & Forecast
  10.2.1. By Drug Type
  10.2.2. By Dosage Form
  10.2.3. By Route of Administration
  10.2.4. By Distribution Channel
  10.2.5. By End User
  10.2.6. By Country
10.3. Europe: Country Analysis
  10.3.1. France Reiter’s Syndrome Treatment Market Outlook
    10.3.1.1. Market Size & Forecast
      10.3.1.1.1. By Value
    10.3.1.2. Market Share & Forecast
      10.3.1.2.1. By Drug Type
      10.3.1.2.2. By Dosage Form
      10.3.1.2.3. By Route of Administration
      10.3.1.2.4. By Distribution Channel
      10.3.1.2.5. By End User
  10.3.2. Germany Reiter’s Syndrome Treatment Market Outlook
    10.3.2.1. Market Size & Forecast
      10.3.2.1.1. By Value
    10.3.2.2. Market Share & Forecast
      10.3.2.2.1. By Drug Type
      10.3.2.2.2. By Dosage Form
      10.3.2.2.3. By Route of Administration
      10.3.2.2.4. By Distribution Channel
      10.3.2.2.5. By End User
  10.3.3. United Kingdom Reiter’s Syndrome Treatment Market Outlook
    10.3.3.1. Market Size & Forecast
      10.3.3.1.1. By Value
    10.3.3.2. Market Share & Forecast
      10.3.3.2.1. By Drug Type
      10.3.3.2.2. By Dosage Form
      10.3.3.2.3. By Route of Administration
      10.3.3.2.4. By Distribution Channel
      10.3.3.2.5. By End User
  10.3.4. Italy Reiter’s Syndrome Treatment Market Outlook
    10.3.4.1. Market Size & Forecast
      10.3.4.1.1. By Value
    10.3.4.2. Market Share & Forecast
      10.3.4.2.1. By Drug Type
      10.3.4.2.2. By Dosage Form
      10.3.4.2.3. By Route of Administration
      10.3.4.2.4. By Distribution Channel
      10.3.4.2.5. By End User
  10.3.5. Spain Reiter’s Syndrome Treatment Market Outlook
    10.3.5.1. Market Size & Forecast
      10.3.5.1.1. By Value
    10.3.5.2. Market Share & Forecast
      10.3.5.2.1. By Drug Type
      10.3.5.2.2. By Dosage Form
      10.3.5.2.3. By Route of Administration
      10.3.5.2.4. By Distribution Channel
      10.3.5.2.5. By End User

11. ASIA-PACIFIC REITER’S SYNDROME TREATMENT MARKET OUTLOOK

11.1. Market Size & Forecast
  11.1.1. By Value
11.2. Market Share & Forecast
  11.2.1. By Drug Type
  11.2.2. By Dosage Form
  11.2.3. By Route of Administration
  11.2.4. By Distribution Channel
  11.2.5. By End User
  11.2.6. By Country
11.3. Asia-Pacific: Country Analysis
  11.3.1. China Reiter’s Syndrome Treatment Market Outlook
    11.3.1.1. Market Size & Forecast
      11.3.1.1.1. By Value
    11.3.1.2. Market Share & Forecast
      11.3.1.2.1. By Drug Type
      11.3.1.2.2. By Dosage Form
      11.3.1.2.3. By Route of Administration
      11.3.1.2.4. By Distribution Channel
      11.3.1.2.5. By End User
  11.3.2. India Reiter’s Syndrome Treatment Market Outlook
    11.3.2.1. Market Size & Forecast
      11.3.2.1.1. By Value
    11.3.2.2. Market Share & Forecast
      11.3.2.2.1. By Drug Type
      11.3.2.2.2. By Dosage Form
      11.3.2.2.3. By Route of Administration
      11.3.2.2.4. By Distribution Channel
      11.3.2.2.5. By End User
  11.3.3. South Korea Reiter’s Syndrome Treatment Market Outlook
    11.3.3.1. Market Size & Forecast
      11.3.3.1.1. By Value
    11.3.3.2. Market Share & Forecast
      11.3.3.2.1. By Drug Type
      11.3.3.2.2. By Dosage Form
      11.3.3.2.3. By Route of Administration
      11.3.3.2.4. By Distribution Channel
      11.3.3.2.5. By End User
  11.3.4. Japan Reiter’s Syndrome Treatment Market Outlook
    11.3.4.1. Market Size & Forecast
      11.3.4.1.1. By Value
    11.3.4.2. Market Share & Forecast
      11.3.4.2.1. By Drug Type
      11.3.4.2.2. By Dosage Form
      11.3.4.2.3. By Route of Administration
      11.3.4.2.4. By Distribution Channel
      11.3.4.2.5. By End User
  11.3.5. Australia Reiter’s Syndrome Treatment Market Outlook
    11.3.5.1. Market Size & Forecast
      11.3.5.1.1. By Value
    11.3.5.2. Market Share & Forecast
      11.3.5.2.1. By Drug Type
      11.3.5.2.2. By Dosage Form
      11.3.5.2.3. By Route of Administration
      11.3.5.2.4. By Distribution Channel
      11.3.5.2.5. By End User

12. SOUTH AMERICA REITER’S SYNDROME TREATMENT MARKET OUTLOOK

12.1. Market Size & Forecast
  12.1.1. By Value
12.2. Market Share & Forecast
  12.2.1. By Drug Type
  12.2.2. By Dosage Form
  12.2.3. By Route of Administration
  12.2.4. By Distribution Channel
  12.2.5. By End User
  12.2.6. By Country
12.3. South America: Country Analysis
  12.3.1. Brazil Reiter’s Syndrome Treatment Market Outlook
    12.3.1.1. Market Size & Forecast
      12.3.1.1.1. By Value
    12.3.1.2. Market Share & Forecast
      12.3.1.2.1. By Drug Type
      12.3.1.2.2. By Dosage Form
      12.3.1.2.3. By Route of Administration
      12.3.1.2.4. By Distribution Channel
      12.3.1.2.5. By End User
  12.3.2. Argentina Reiter’s Syndrome Treatment Market Outlook
    12.3.2.1. Market Size & Forecast
      12.3.2.1.1. By Value
    12.3.2.2. Market Share & Forecast
      12.3.2.2.1. By Drug Type
      12.3.2.2.2. By Dosage Form
      12.3.2.2.3. By Route of Administration
      12.3.2.2.4. By Distribution Channel
      12.3.2.2.5. By End User
  12.3.3. Colombia Reiter’s Syndrome Treatment Market Outlook
    12.3.3.1. Market Size & Forecast
      12.3.3.1.1. By Value
    12.3.3.2. Market Share & Forecast
      12.3.3.2.1. By Drug Type
      12.3.3.2.2. By Dosage Form
      12.3.3.2.3. By Route of Administration
      12.3.3.2.4. By Distribution Channel
      12.3.3.2.5. By End User

13. MIDDLE EAST AND AFRICA REITER’S SYNDROME TREATMENT MARKET OUTLOOK

13.1. Market Size & Forecast
  13.1.1. By Value
13.2. Market Share & Forecast
  13.2.1. By Drug Type
  13.2.2. By Dosage Form
  13.2.3. By Route of Administration
  13.2.4. By Distribution Channel
  13.2.5. By End User
  13.2.6. By Country
13.3. MEA: Country Analysis
  13.3.1. South Africa Reiter’s Syndrome Treatment Market Outlook
    13.3.1.1. Market Size & Forecast
      13.3.1.1.1. By Value
    13.3.1.2. Market Share & Forecast
      13.3.1.2.1. By Drug Type
      13.3.1.2.2. By Dosage Form
      13.3.1.2.3. By Route of Administration
      13.3.1.2.4. By Distribution Channel
      13.3.1.2.5. By End User
  13.3.2. Saudi Arabia Reiter’s Syndrome Treatment Market Outlook
    13.3.2.1. Market Size & Forecast
      13.3.2.1.1. By Value
    13.3.2.2. Market Share & Forecast
      13.3.2.2.1. By Drug Type
      13.3.2.2.2. By Dosage Form
      13.3.2.2.3. By Route of Administration
      13.3.2.2.4. By Distribution Channel
      13.3.2.2.5. By End User
  13.3.3. UAE Reiter’s Syndrome Treatment Market Outlook
    13.3.3.1. Market Size & Forecast
      13.3.3.1.1. By Value
    13.3.3.2. Market Share & Forecast
      13.3.3.2.1. By Drug Type
      13.3.3.2.2. By Dosage Form
      13.3.3.2.3. By Route of Administration
      13.3.3.2.4. By Distribution Channel
      13.3.3.2.5. By End User

14. MARKET DYNAMICS

14.1. Drivers
14.2. Challenges

15. MARKET TRENDS & DEVELOPMENTS

16. COMPETITIVE LANDSCAPE

16.1. F. Hoffmann-La Roche AG
16.2. Pfizer, Inc.
16.3. Novartis AG
16.4. Cipla Inc.
16.5. Dr. Reddy’s Laboratories Ltd.
16.6. Abbott Laboratories, Inc.
16.7. GlaxoSmithKline plc
16.8. Sun Pharmaceutical Industries Ltd
16.9. Teva Pharmaceutical Industries Ltd
16.10. AstraZeneca, Plc.

17. STRATEGIC RECOMMENDATIONS

18. ABOUT US & DISCLAIMER